Geniculate Artery Embolization for Osteoarthritis

Description

The need for exploration of more definitive and cost effective non-arthroplasty treatments of osteoarthritis (OA) has been demonstrated by the orthopedic and health economic research. Embolotherapy of neovessels associated with OA joints has been shown to be promising in patients with knee OA. There is a need for level one evidence drawn from randomized clinical trials to prove the safety, feasibility and efficacy of knee embolotherapy compared to standard of care. This randomized pilot study will assign 10 patients with mild-moderate OA to undergo geniculate artery embolization plus standard of care (defined in this study as: physical therapy and oral anti-inflammatory medications, with a maximum of 1 joint injection at the time of enrollment) and 10 patients to receive only medical standard of care (also having had a maximum of 1 joint injection prior to enrollment). The goal of this pilot study is to obtain preliminary estimates of safety and efficacy of embolotherapy to provide sustained symptom control and modify disease progression in patients with mild to moderate knee OA.

Conditions

Osteo Arthritis Knee, Arthritis, Osteoarthritis, Osteoarthritis, Knee

Talk to us

Study Overview

On this page

Study Details

Study overview

The need for exploration of more definitive and cost effective non-arthroplasty treatments of osteoarthritis (OA) has been demonstrated by the orthopedic and health economic research. Embolotherapy of neovessels associated with OA joints has been shown to be promising in patients with knee OA. There is a need for level one evidence drawn from randomized clinical trials to prove the safety, feasibility and efficacy of knee embolotherapy compared to standard of care. This randomized pilot study will assign 10 patients with mild-moderate OA to undergo geniculate artery embolization plus standard of care (defined in this study as: physical therapy and oral anti-inflammatory medications, with a maximum of 1 joint injection at the time of enrollment) and 10 patients to receive only medical standard of care (also having had a maximum of 1 joint injection prior to enrollment). The goal of this pilot study is to obtain preliminary estimates of safety and efficacy of embolotherapy to provide sustained symptom control and modify disease progression in patients with mild to moderate knee OA.

Geniculate Artery Embolization for Osteoarthritis: Pilot Study

Geniculate Artery Embolization for Osteoarthritis

Condition
Osteo Arthritis Knee
Intervention / Treatment

-

Contacts and Locations

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55455

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Unilaterally dominant symptomatic osteoarthritis (bilateral radiographic OA will not exclude)
  • * Patients who are symptomatically refractory of at least 3 months of medical and/or rehabilitation measures (anti-inflammatory drugs, and/or physical therapy, and/or strength conditioning, and/or 0-1 intra-articular injections of the affected knee)
  • * Kellgren-Lawrence grade 1, 2, or 3 on radiograph of the knee
  • * Patients who are willing to comply with the protocol requirements and willing to undergo non-contrast MRI 1-30 days prior to procedure and at 12 months following procedure
  • * Patients who are willing to comply with regular follow up during the 12 month follow-up period
  • * Patients who have been evaluated by an orthopaedic surgeon or sports medicine provider and deemed to not be a current candidate for partial or total knee arthroplasty. These patients do, however, need to be considered a potential candidate for partial or total knee as an end point following the natural history of osteoarthritis.
  • * Patients with WOMAC Score \>=6 in at least 2 categories
  • * Patients with a weight \>250 pounds
  • * Patients with advanced peripheral arterial disease (resting ABI \<= 0.9)
  • * Patients with known significant peripheral arterial disease precluding common femoral catheterization
  • * Patients who do smoke or have smoked tobacco regularly (smoking 1 or more tobacco product(s) per week) within the last year
  • * Patients with diabetes who have a hemoglobin A1C of \>9%
  • * Patients who have undergone previous lower extremity embolization
  • * Patients with uncontrolled emotional disorders per patient medical history
  • * Patients with chronic pain syndrome or currently under a pain contract
  • * Patients with anatomic variants involving the lower extremities which would increase the risk of non-target embolization
  • * Patients with renal insufficiency based on an estimated GFR\<45 ml/min who are not already on hemodialysis.
  • * Patients with an abnormal INR (\>1.5).
  • * Patients with a platelet count \<50x109/L.
  • * Patients who are currently receiving medications for anticoagulation which cannot safely be held for the procedure and for 7 days post-procedure.
  • * Patients with a known severe allergy to iodine which cannot be adequately pre-medicated
  • * Patients who are pregnant or intend to become pregnant within 6 months of the procedure
  • * Patients with a contraindication to drugs used for moderate sedation during interventional procedures, including Midazolam and Fentanyl
  • * Patients with a life expectancy \<60 months
  • * Patients who are currently enrolled or who plan to enroll in other investigations that conflict with follow-up testing or confounds data in this trial
  • * Patients with contraindications to medical and physical rehabilitative treatments of OA
  • * Patients with known advanced atherosclerosis
  • * Patients with known current or previous lower extremity fistula
  • * Patients with rheumatoid arthritis or seronegative arthropathies
  • * Patients with prior ipsilateral knee surgery.
  • * Patients with WOMAC Pain Scale \< 6
  • * Patients having received more than one steroid injection in the affected joint or an injection in the affected joint within 3 months of screening

Ages Eligible for Study

40 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Minnesota,

Reza Talaie, MD, PRINCIPAL_INVESTIGATOR, University of Minnesota

Study Record Dates

2026-02-01